Cambrex Corporation (NYSE:CBM) – Research analysts at First Analysis lifted their Q3 2017 earnings estimates for Cambrex Corporation in a research report issued on Monday. First Analysis analyst S. Schwartz now forecasts that the biotechnology company will post earnings of $0.48 per share for the quarter, up from their prior forecast of $0.46. First Analysis also issued estimates for Cambrex Corporation’s Q4 2017 earnings at $1.18 EPS.
CBM has been the topic of a number of other research reports. BidaskClub upgraded Cambrex Corporation from a “hold” rating to a “buy” rating in a research note on Friday, August 4th. Zacks Investment Research cut Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Finally, ValuEngine cut Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $64.00.
WARNING: This piece was first reported by BNB Daily and is owned by of BNB Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/q3-2017-eps-estimates-for-cambrex-corporation-cbm-raised-by-analyst-updated.html.
Cambrex Corporation (CBM) opened at 54.90 on Wednesday. The company has a market cap of $1.79 billion, a price-to-earnings ratio of 20.90 and a beta of 2.28. The stock has a 50 day moving average of $59.25 and a 200-day moving average of $55.49. Cambrex Corporation has a 52-week low of $38.30 and a 52-week high of $62.95.
Cambrex Corporation (NYSE:CBM) last released its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.76. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The company had revenue of $134.55 million for the quarter, compared to analyst estimates of $136.82 million. During the same quarter last year, the firm posted $0.68 earnings per share. The company’s quarterly revenue was up 13.4% compared to the same quarter last year.
In related news, VP Samantha Hanley sold 14,000 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $57.56, for a total value of $805,840.00. Following the sale, the vice president now owns 1,500 shares in the company, valued at approximately $86,340. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $54.19, for a total value of $650,280.00. Following the completion of the sale, the chief executive officer now owns 95,328 shares in the company, valued at approximately $5,165,824.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 70,656 shares of company stock worth $4,064,423. 2.48% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of CBM. Nisa Investment Advisors LLC boosted its stake in Cambrex Corporation by 9.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after buying an additional 150 shares during the period. Creative Planning boosted its stake in Cambrex Corporation by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,093 shares during the period. Flinton Capital Management LLC boosted its stake in Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares during the period. YorkBridge Wealth Partners LLC boosted its stake in Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares during the period. Finally, Meeder Asset Management Inc. acquired a new stake in Cambrex Corporation during the first quarter worth $109,000. Institutional investors and hedge funds own 98.28% of the company’s stock.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.